Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Leases (2022 - 2026)

Ovid Therapeutics filings provide 5 years of Leases readings, the most recent being $11.3 million for Q1 2026.

  • Quarterly Leases fell 9.68% to $11.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Mar 2026, down 9.68% year-over-year, with the annual reading at $11.6 million for FY2025, 9.28% down from the prior year.
  • Leases hit $11.3 million in Q1 2026 for Ovid Therapeutics, down from $11.6 million in the prior quarter.
  • Across five years, Leases topped out at $15.7 million in Q1 2022 and bottomed at $11.3 million in Q1 2026.
  • Average Leases over 5 years is $13.6 million, with a median of $13.6 million recorded in 2024.
  • The largest annual shift saw Leases decreased 6.51% in 2023 before it fell 9.68% in 2026.
  • Ovid Therapeutics' Leases stood at $14.9 million in 2022, then dropped by 6.89% to $13.9 million in 2023, then fell by 7.9% to $12.8 million in 2024, then decreased by 9.28% to $11.6 million in 2025, then fell by 2.69% to $11.3 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Leases are $11.3 million (Q1 2026), $11.6 million (Q4 2025), and $11.9 million (Q3 2025).